Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
Investigators sought to determine whether a monogenic cause substantially increases the risk for premature cardiovascular disease in patients with familial hypercholesterolemia.
ARO-ANG3 reduces production of ANGPTL3, which has been shown to lower serum LDL as well as serum and liver triglyceride.
Ezallor Sprinkle is intended for patients who have difficulty swallowing.
Livalo is indicated for pediatric patients ≥8 years old with HeFH to reduce TC, LDL-C, and Apo-B.
A low-density lipoprotein-cholesterol level >4.9 mmol/L in addition to the Dutch Lipid Clinic Network Criteria score may help identify probable/definite or possible familial hypercholesterolemia.
Data from a blood donor screening program could represent a novel strategy for identifying familial hypercholesterolemia.
The FDA has approved Praluent (alirocumab; Sanofi and Regeneron), a PCSK9 inhibitor, to reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
In patients with familial premature myocardial infarction, applying clinical and mutation criteria for familial hypercholesterolemia only identified a minor fraction of individuals with the disorder.
Researchers examined whether lipoprotein(a) cholesterol life-years can effectively measure cumulative risk for atherosclerotic cardiovascular disease and questioned whether this metric may apply to the incidence of aortic valve calcification.
